Welcome to our dedicated page for Immucell SEC filings (Ticker: ICCC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ImmuCell filings document material events and governance matters for an animal health biologics company built around First Defense. Form 8-K reports record preliminary and annual financial results, board retirements and appointments, senior-officer employment agreements, and settlement of claims tied to a prior development services and commercial supply agreement.
Definitive proxy materials cover director matters, board oversight, executive compensation, and equity-award disclosures. The filing record also includes exhibits with company press releases addressing product sales, financial condition, strategic focus, and related operating updates.
ImmuCell Corp director David Scott Tomsche received a grant of stock options as part of his compensation. He was awarded 11,933 non-qualified stock options to buy ImmuCell common stock at an exercise price of $7.60 per share, expiring on April 15, 2036.
The options vest over time: 3,977 become exercisable on April 15, 2027, another 3,977 on April 15, 2028, and 3,979 on April 15, 2029. This is a compensation-related award, not an open-market purchase or sale of shares.
ImmuCell director Gloria F. Basse received a grant of 11,933 non-qualified stock options to buy ImmuCell common stock. The options have an exercise price of $7.60 per share and expire on April 15, 2036.
All 11,933 options were awarded as compensation and are held directly. According to the vesting schedule, 3,977 options become exercisable on each of April 15, 2027 and April 15, 2028, and 3,979 options become exercisable on April 15, 2029.
ImmuCell Corp director Paul R. Wainman received a new stock option grant as part of his compensation. He was awarded options to buy 11,933 shares of ImmuCell common stock at an exercise price of $7.60 per share, expiring on April 15, 2036.
The options vest over three years: 3,977 shares become exercisable on each of April 15, 2027 and April 15, 2028, and 3,979 shares on April 15, 2029. After this grant, Wainman holds 11,933 stock options directly, indicating a compensation-related equity award rather than an open-market purchase or sale.
ImmuCell Corporation is soliciting proxies for its remote Annual Meeting of Stockholders to be held June 11, 2026, with a record date of April 13, 2026. The meeting will consider: election of seven directors; a non-binding advisory vote on executive compensation; approval of the 2025 Stock Option and Incentive Plan; an amendment to the Certificate of Incorporation to add officer exculpation under Delaware law; and ratification of Wipfli LLP as independent auditors.
The 2025 Plan would authorize up to 650,000 shares. The proxy discloses director pay changes (non-employee director annual fee increased to $40,000 effective January 1, 2026), named executive officer compensation details (e.g., CEO total 2025 compensation $675,934), outstanding option and plan balances (total options outstanding 801,760; weighted-average exercise price $6.20), and governance items including committee structures and related-party disclosure.
ImmuCell Corp. director Bryan K. Gathagan received a grant of non-qualified stock options for 10,000 shares of common stock. The options have an exercise price of $5.49 per share, become exercisable on April 16, 2028, and expire on April 16, 2030. Following this grant, he holds 10,000 options directly.
ImmuCell Corp. director Paul R. Wainman received a grant of stock options as part of his compensation. On April 16, 2025, he was awarded non-qualified options to acquire 10,000 shares of ImmuCell common stock at an exercise price of $5.49 per share.
The options become exercisable on April 16, 2028 and expire on April 16, 2030. Following this grant, Wainman holds 10,000 stock options directly, and this filing does not show any sales or open-market purchases of common stock.
ImmuCell Corp director David Scott Tomsche received a grant of 10,000 stock options as compensation. These non-qualified stock options give him the right to buy 10,000 shares of ImmuCell common stock at an exercise price of $5.49 per share. Following this award, his reported derivative holdings from this grant total 10,000 options, which become exercisable on April 16, 2028 and expire on April 16, 2030. This is a routine equity incentive award rather than an open-market share purchase or sale.
ImmuCell Corp. vice president Bobbi Jo Brockmann received a grant of 5,000 incentive stock options for company common stock. The options carry an exercise price of $5.49 per share and relate to 5,000 underlying common shares. They are reported as directly owned and expire on April 16, 2030.
ImmuCell Corp. director Steven T. Rosgen received a grant of 10,000 non-qualified stock options on Common Stock. The options have an exercise price of $5.49 per share, become exercisable on April 16, 2028, and expire on April 16, 2030. Following this compensation-related award, he holds 10,000 options directly.
ImmuCell Corp. director Gloria F. Basse received a grant of 10,000 non-qualified stock options on Common Stock. These options were awarded as compensation at an exercise price of $5.49 per share, allowing her to buy up to 10,000 shares at that price if she chooses to exercise.
After this award, she holds options on 10,000 shares in total, with the options scheduled to become exercisable on April 16, 2028 and expiring on April 16, 2030. This is a routine equity incentive grant rather than an open-market stock purchase or sale.